Robert McLachlan is an internationally recognised clinician-scientist in male reproductive health. His basic research examines the genetic & endocrine regulation of sperm production. His clinical studies span male fertility regulation, the use of assisted reproductive treatments, and the evidence-based use of androgen replacement. As Director of Andrology Australia, he has a leading national role in professional and community education, developing research capacity and male health advocacy.
The nuclear hormone receptors (NRs) translate hormonal, metabolic & pathophysiological signals into gene regulation, and several NRs are very important in human health. NRs are important therapeutics targets in the treatment of dyslipidemia, insulin insensitivity and breast cancer. Our data identifies new and novel NR targets that can be therapeutically/pharmacologically exploited in the context of exercise capacity, metabolic disease and breast cancer.
Reproductive health critically impacts a woman’s wellbeing, irrespective of her choice to have children. The ovary and its hormones govern physiological events regulating health at puberty, across the menstrual cycle, during the establishment and maintenance of pregnancy, and in parturition, lactation and menopause. The major health burdens concerning ovaries that we are studying include polycystic ovarian syndrome and assisted reproductive technologies used to treat infertility.
This research deals with the interaction between the reproductive system and the immune system, providing a unique perspective on two biological systems that are normally considered separately. This research may help to improve the treatment of infertility, reproductive tract infections and testicular cancer, but may also lead to new treatments for inflammatory diseases that hospitalise or kill many thousands of patients each year, and for preventing graft failure in transplant recipients.
Male Reproductive Health Including Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$727,685.00
Summary
My previous contributions to Andrology and Endocrinology of the Testis provide me with a significant breadth of expertise and a sustained record of contribution to Men’s Reproductive Health. My recent research effort has focused on Urology and prostate cancer. Through my prostate cancer research program, my overall strategy is to understand the biology of the prostate gland to enable the development of new therapies for prostate cancer, as well as for BPH (enlargement of the prostate) and prosta ....My previous contributions to Andrology and Endocrinology of the Testis provide me with a significant breadth of expertise and a sustained record of contribution to Men’s Reproductive Health. My recent research effort has focused on Urology and prostate cancer. Through my prostate cancer research program, my overall strategy is to understand the biology of the prostate gland to enable the development of new therapies for prostate cancer, as well as for BPH (enlargement of the prostate) and prostatitis (inflammation of the prostate gland).Read moreRead less
Molecular Characterisation Of Steroid Hormone-dependent Diseases Of The Cardiovascular And Reproductive Systems
Funder
National Health and Medical Research Council
Funding Amount
$1,085,790.00
Summary
Peter Fuller is both a molecular and clinical endocrinologist. His research examines steroid hormones in cardiovascular disease and cancer. The hormone aldosterone controls blood pressure and has a significant role in cardiac failure. This work will enable the development of tissue-specific blockers of aldosterone for the treatment of cardiovascular disease. Steroid hormones also have a role in granulosa cell tumours of the ovary and breast cancer; new insights will lead to novel therapeutics.